92 related articles for article (PubMed ID: 8576096)
1. Transfection of human melanoma cells with type I interleukin-1 (IL-1) receptor cDNA rendered them IL-1-responsive and revealed the importance of ODC activity down-regulation in IL-1-induced growth inhibition.
Yang D; Hayashi H; Hiyama Y; Takii T; Onozaki K
J Biochem; 1995 Oct; 118(4):802-9. PubMed ID: 8576096
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative effect of IL-1 is mediated by p38 mitogen-activated protein kinase in human melanoma cell A375.
Itoh S; Hattori T; Hayashi H; Mizutani Y; Todo M; Takii T; Yang D; Lee JC; Matsufuji S; Murakami Y; Chiba T; Onozaki K
J Immunol; 1999 Jun; 162(12):7434-40. PubMed ID: 10358197
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1-induced growth inhibition of human melanoma cells. Interleukin-1-induced antizyme expression is responsible for ornithine decarboxylase activity down-regulation.
Yang D; Hayashi H; Takii T; Mizutani Y; Inukai Y; Onozaki K
J Biol Chem; 1997 Feb; 272(6):3376-83. PubMed ID: 9013579
[TBL] [Abstract][Full Text] [Related]
4. Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor.
Endo Y; Matsushima K; Onozaki K; Oppenheim JJ
J Immunol; 1988 Oct; 141(7):2342-8. PubMed ID: 2971724
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 1 (IL-1) production is not essential for acquired resistance of human A375 melanoma cells to anti-proliferative effect of IL-1.
Itoh S; Hayashi H; Watanabe N; Kobayashi Y; Takii T; Onozaki K
Int J Cancer; 1996 Mar; 65(6):805-11. PubMed ID: 8631596
[TBL] [Abstract][Full Text] [Related]
6. Resistance to the anti-proliferative effect of IL-1 on human melanoma cell line is associated with endogenous production of IL-1 and IL-6.
Araki M; Yano T; Hayashi H; Takii T; Suzuki K; Onozaki K
Int J Cancer; 1994 Jan; 56(2):275-80. PubMed ID: 8314311
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.
Silvani A; Ferrari G; Paonessa G; Toniatti C; Parmiani G; Colombo MP
Cancer Res; 1995 May; 55(10):2200-5. PubMed ID: 7743524
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to the anti-proliferative effect of interleukin-1 and interleukin-6 is a recessive phenotype in A375 human melanoma cells.
Itoh S; Hayashi H; Yang D; Takii T; Onozaki K
Melanoma Res; 1997 Dec; 7(6):455-62. PubMed ID: 9464617
[TBL] [Abstract][Full Text] [Related]
9. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines.
Morinaga Y; Suzuki H; Takatsuki F; Akiyama Y; Taniyama T; Matsushima K; Onozaki K
J Immunol; 1989 Dec; 143(11):3538-42. PubMed ID: 2584706
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells.
Mimnaugh EG; Monti E; Sebers S; Stetler-Stevenson M; Sinha BK
Oncol Res; 1992; 4(10):401-12. PubMed ID: 1292755
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of in vitro antitumor effects of interleukin 1 (IL 1).
Endo Y; Matsushima K; Oppenheim JJ
Immunobiology; 1986 Sep; 172(3-5):316-22. PubMed ID: 3492432
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
[TBL] [Abstract][Full Text] [Related]
13. Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
Porter CW; Ganis B; Rustum Y; Wrzosek C; Kramer DL; Bergeron RJ
Cancer Res; 1994 Nov; 54(22):5917-24. PubMed ID: 7954423
[TBL] [Abstract][Full Text] [Related]
14. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
Cancer Res; 1991 Feb; 51(3):769-74. PubMed ID: 1824825
[TBL] [Abstract][Full Text] [Related]
15. MSH receptors and the response of human A375 melanoma cells to interleukin-1 beta.
Baumann JB; Bagutti C; Siegrist W; Christen E; Zumsteg U; Eberle AN
J Recept Signal Transduct Res; 1997; 17(1-3):199-210. PubMed ID: 9029491
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 enhances the growth of human melanoma cells derived form primary but not from metastatic tumours.
García-Vázquez MD; Boyano MD; Cañavate ML; Gardeazabal J; de Galdeano AG; López-Michelena T; Ratón JA; Izu R; Díaz-Ramón JL; Díaz-Pérez JL
Eur Cytokine Netw; 2000 Dec; 11(4):654-61. PubMed ID: 11125310
[TBL] [Abstract][Full Text] [Related]
17. Differential cytostatic activity of monocyte-derived cytokines against human melanoma cells.
te Velde AA; vd Wiel-v Kemenade E; Figdor CG
Int J Cancer; 1992 Mar; 50(5):746-51. PubMed ID: 1544709
[TBL] [Abstract][Full Text] [Related]
18. CHOP, a basic leucine zipper transcriptional factor, contributes to the antiproliferative effect of IL-1 on A375 human melanoma cells through augmenting transcription of IL-6.
Hattori T; Itoh S; Hayashi H; Chiba T; Takii T; Yoshizaki K; Onozaki K
J Interferon Cytokine Res; 2001 May; 21(5):323-32. PubMed ID: 11429163
[TBL] [Abstract][Full Text] [Related]
19. Resistance to IL-1 anti-proliferative effect, accompanied by characteristics of advanced melanoma, permits invasion of human melanoma cells in vitro, but not metastasis in the nude mouse.
Hayashi H; Shimizu R; Fujii K; Itoh S; Yang D; Onozaki K
Int J Cancer; 1997 May; 71(3):416-21. PubMed ID: 9139878
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1-inducible tumor growth arrest is characterized by activation of cell type-specific "early" gene expression programs.
Rangnekar VV; Waheed S; Rangnekar VM
J Biol Chem; 1992 Mar; 267(9):6240-8. PubMed ID: 1372901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
